NO951630L - Fremgangsmåte for administrering av azithromycin - Google Patents

Fremgangsmåte for administrering av azithromycin

Info

Publication number
NO951630L
NO951630L NO951630A NO951630A NO951630L NO 951630 L NO951630 L NO 951630L NO 951630 A NO951630 A NO 951630A NO 951630 A NO951630 A NO 951630A NO 951630 L NO951630 L NO 951630L
Authority
NO
Norway
Prior art keywords
azithromycin
administration
Prior art date
Application number
NO951630A
Other languages
English (en)
Other versions
NO951630D0 (no
NO314386B1 (no
Inventor
William John Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO951630(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO951630D0 publication Critical patent/NO951630D0/no
Publication of NO951630L publication Critical patent/NO951630L/no
Publication of NO314386B1 publication Critical patent/NO314386B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO19951630A 1994-04-29 1995-04-28 Tablett- og pulverformulering for oral suspenson inneholdende azithromycin NO314386B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (3)

Publication Number Publication Date
NO951630D0 NO951630D0 (no) 1995-04-28
NO951630L true NO951630L (no) 1995-10-30
NO314386B1 NO314386B1 (no) 2003-03-17

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951630A NO314386B1 (no) 1994-04-29 1995-04-28 Tablett- og pulverformulering for oral suspenson inneholdende azithromycin

Country Status (31)

Country Link
US (2) US5605889A (no)
EP (1) EP0679400B1 (no)
JP (3) JPH07300420A (no)
KR (1) KR100354310B1 (no)
CN (1) CN1088362C (no)
AP (1) AP566A (no)
AT (1) ATE183395T1 (no)
AU (1) AU709328B2 (no)
CA (1) CA2148071C (no)
CO (1) CO4560547A1 (no)
DE (1) DE69511451T2 (no)
DK (1) DK0679400T3 (no)
DZ (1) DZ1877A1 (no)
ES (1) ES2136247T3 (no)
FI (1) FI952060A (no)
GR (1) GR3031290T3 (no)
HU (1) HUT75244A (no)
IL (1) IL113437A (no)
LV (1) LV10918B (no)
MA (1) MA23533A1 (no)
NO (1) NO314386B1 (no)
NZ (1) NZ548384A (no)
OA (1) OA10151A (no)
RU (1) RU2128998C1 (no)
SI (1) SI0679400T1 (no)
TN (1) TNSN95046A1 (no)
TW (1) TW499311B (no)
UA (1) UA34464C2 (no)
UY (1) UY23935A1 (no)
YU (1) YU49483B (no)
ZA (1) ZA953439B (no)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100232297B1 (ko) † 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
BR9607189A (pt) * 1995-02-08 1997-11-11 Yamanouchi Europ Bv Formas de dosagem oral contendo um antibiótico de b-lactama
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
JP2001526234A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション 経口投与が可能な固形リバビリン投薬の形態およびそれらの製造プロセス
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
HU230440B1 (hu) * 1999-03-31 2016-06-28 Janssen Pharmaceutica N.V Előgélesített keményítőt tartalmazó szabályozott felszabadulású készítmények
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6528492B1 (en) * 2000-07-25 2003-03-04 Instituto De Investigacion En Quimica Aplicada S.C. Single-step process for preparing 7, 16-deoxy-2-aza-10-0-cladinosil-12-0-desosaminil-4, 5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1) hexadeca-1(2)-en-ona and obtaining a new form of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a
EP1313749B1 (en) 2000-08-23 2005-10-12 Wockhardt Limited Process for preparation of anhydrous azithromycin
AU3240602A (en) * 2000-11-06 2002-05-15 Invitrogen Corp Dry powder cells and cell culture reagents and methods of production thereof
WO2002040036A1 (fr) * 2000-11-15 2002-05-23 Masao Sugamata Medicaments destines a la prevention ou au traitement de l'endometriose ou du myome uterin
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DK1446010T3 (da) 2001-10-18 2009-06-22 Teva Pharma Stabiliseret azithromycin-sammensætning
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
EP1476191A2 (en) * 2002-01-16 2004-11-17 Pepgen Corporation Oral administration of interferon-tau
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
CA2517004A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
BRPI0410098A (pt) * 2003-05-06 2006-05-16 Nirmal Mulye formulação de liberação controlada de derivados de eritromicina
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE602004019288D1 (de) * 2003-07-24 2009-03-19 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
TWI366442B (en) 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513146A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
CN101111245A (zh) * 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
JP2008528583A (ja) * 2005-03-07 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 経口懸濁用のアジスロマイシン粉末組成物
DK2422783T3 (en) 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition
WO2007018192A1 (ja) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 口腔内崩壊錠剤
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
TR201902125T4 (tr) 2012-02-06 2019-03-21 Merial Inc Si̇stemi̇k olarak etki̇ eden akti̇f ajanlari i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
WO2013129889A2 (ko) 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
WO2015070131A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (en) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd 2'-modified erythromycin or derivative thereof
TW271400B (no) * 1992-07-30 1996-03-01 Pfizer
WO1995009601A1 (en) 1993-10-01 1995-04-13 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
KR100232297B1 (ko) 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제

Also Published As

Publication number Publication date
DK0679400T3 (da) 1999-12-06
KR100354310B1 (ko) 2002-12-26
FI952060A0 (fi) 1995-04-28
DZ1877A1 (fr) 2002-02-17
CA2148071A1 (en) 1995-10-30
US5605889A (en) 1997-02-25
CN1114879A (zh) 1996-01-17
LV10918B (en) 1996-06-20
JP2005015466A (ja) 2005-01-20
NZ548384A (en) 2008-04-30
HUT75244A (en) 1997-05-28
CN1088362C (zh) 2002-07-31
IL113437A0 (en) 1995-07-31
LV10918A (lv) 1995-12-20
JPH07300420A (ja) 1995-11-14
CA2148071C (en) 2000-10-17
CO4560547A1 (es) 1998-02-10
AP566A (en) 1996-11-22
NO951630D0 (no) 1995-04-28
UA34464C2 (uk) 2001-03-15
RU2128998C1 (ru) 1999-04-20
FI952060A (fi) 1995-10-30
AP9500728A0 (en) 1995-04-30
NO314386B1 (no) 2003-03-17
JP2008231120A (ja) 2008-10-02
IL113437A (en) 2001-04-30
UY23935A1 (es) 1995-09-12
TNSN95046A1 (fr) 1996-02-06
MA23533A1 (fr) 1995-12-31
EP0679400A1 (en) 1995-11-02
HU9501206D0 (en) 1995-06-28
AU1771195A (en) 1995-11-09
KR950028764A (ko) 1995-11-22
DE69511451D1 (de) 1999-09-23
DE69511451T2 (de) 1999-12-09
ATE183395T1 (de) 1999-09-15
YU49483B (sh) 2006-08-17
USRE39149E1 (en) 2006-06-27
EP0679400B1 (en) 1999-08-18
AU709328B2 (en) 1999-08-26
RU95106639A (ru) 1997-01-20
OA10151A (en) 1996-12-18
TW499311B (en) 2002-08-21
YU27195A (sh) 1999-03-04
GR3031290T3 (en) 1999-12-31
ZA953439B (en) 1996-10-28
SI0679400T1 (en) 1999-10-31
ES2136247T3 (es) 1999-11-16

Similar Documents

Publication Publication Date Title
NO951630L (no) Fremgangsmåte for administrering av azithromycin
DK42093D0 (da) Administrationsmetode
FI964452A0 (fi) Atsitromysiinin kontrolloidun vapautumisen annostusmuotoja
LV11739A (lv) Eritromicina atvasinajumi iegusanas panemiens un pielietojums
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
BR9611130A (pt) Derivados de 3-aril-5-halógeno-pirona
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
NO982237L (no) FremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO180704C (no) Fremgangsmåte for ekspansjon av tobakk
NO955082L (no) Fremgangsmåte for fremstilling av glutardialdehyd
NO975699L (no) Fremgangsmåte for oksyklorering
BR9607046A (pt) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas
ID18300A (id) Metoda penemperan
IS4285A (is) Aðferð við að hindra útfellingu
NO972129D0 (no) Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater
EE9600007A (et) Diltiaseemi valmistamise meetod
NO964519D0 (no) Fremgangsmåte for fremstilling av chitosanalkylderivater
NO961004L (no) Fremgangsmåte for fremstilling av N-acetyl-D-glukosamin-deacetylase
KR970001363A (ko) 세펨 유도체의 제조방법
FI960790A0 (fi) Menetelmä fluoreenibisfenolin valmistamiseksi
UA24720A (uk) Спосіб алотраhсплаhтації hирки
UA25110A (uk) Спосіб біліосорбції
KR970006255A (ko) 클로로포름의 제조방법
UA25109A (uk) Спосіб створюваhhя холедоходуодеhоаhастомозу
EE03376B1 (et) Meetod ravimuda ettevalmistamiseks